3-Amino-7-dimethylamino-phenothiazin | 5627-42-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻嗪类
• 英文名称: 3-Amino-7-dimethylamino-phenothiazin
• 英文别名: N,N-dimethyl-10H-phenothiazine-3,7-diamine；N³,N³-dimethyl-phenothiazine-3,7-diyldiamine；N³,N³-Dimethyl-phenothiazin-3,7-diyldiamin；7-N,7-N-dimethyl-10H-phenothiazine-3,7-diamine
• CAS: 5627-42-9
• 化学式: C₁₄H₁₅N₃S
• 分子量: 257.359
• InChiKey: YPQAXKHZWGSIRQ-UHFFFAOYSA-N

物化性质

• 沸点：
  505.8±50.0 °C(Predicted)
• 密度：
  1.274±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  66.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-Amino-7-dimethylamino-phenothiazin 生成 azure A
  参考文献：
  名称：

  Gnehm; Kaufler, Chemische Berichte, 1906, vol. 39, p. 1016

  摘要：

  DOI：
• 作为产物：
  描述：

  亚甲基蓝阳离子 在 氨 作用下， 生成 3-Amino-7-dimethylamino-phenothiazin
  参考文献：
  名称：

  Gnehm; Kaufler, Chemische Berichte, 1906, vol. 39, p. 1016

  摘要：

  DOI：

文献信息

• MATERIALS AND METHODS RELATING TO PROTEIN AGGREGATION IN NEURODEGENERATIVE DISEASE
  申请人：Wista Laboratories Ltd.

  公开号：EP1352077B1

  公开（公告）日：2010-10-06
• Materials and methods relating to protein aggregation in neurodegenerative disease
  申请人：Wischik Claude Michel

  公开号：US20090075984A1

  公开（公告）日：2009-03-19

  The present invention is directed to methods for the treatment or prophylaxis of a tauopathy comprising administering to a patient in need thereof a medicament comprising a phenothiazine.
• Integumentary System Therapy
  申请人：Lebovitz Russell M.

  公开号：US20170050044A1

  公开（公告）日：2017-02-23

  Described are methods, kits, apparatus, and compositions for integumentary system therapy. For example, a method for therapy may include providing a subject in need of therapy for a condition. The condition may be associated with a substrate located in the subject's integumentary system. The method may include contacting a therapeutic agent and the substrate in the subject's integumentary system. The method may include modulating a depth of at least one ionic species in the subject's integumentary system. The at least one ionic species may include one or more of: the therapeutic agent; a bound therapeutic agent:substrate complex; and a reaction product of one or both of the therapeutic agent and the substrate. The method may be effective to at least partly ameliorate the condition in the subject.
• US7335505B2
  申请人：——

  公开号：US7335505B2

  公开（公告）日：2008-02-26
• US7893054B2
  申请人：——

  公开号：US7893054B2

  公开（公告）日：2011-02-22